Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Rating of “Hold” by Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been given a consensus rating of “Hold” by the twenty-two ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $124.15.

A number of research analysts recently issued reports on ZBH shares. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. JMP Securities reissued a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Stifel Nicolaus increased their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds have recently added to or reduced their stakes in ZBH. Blue Trust Inc. increased its stake in Zimmer Biomet by 165.3% during the 3rd quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock worth $187,000 after acquiring an additional 1,071 shares during the period. International Assets Investment Management LLC increased its stake in shares of Zimmer Biomet by 19,988.0% in the 3rd quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock valued at $11,601,000 after purchasing an additional 106,936 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Zimmer Biomet by 15.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 28,145 shares of the medical equipment provider’s stock valued at $3,038,000 after purchasing an additional 3,859 shares during the last quarter. Tectonic Advisors LLC increased its stake in shares of Zimmer Biomet by 20.8% in the 3rd quarter. Tectonic Advisors LLC now owns 3,647 shares of the medical equipment provider’s stock valued at $394,000 after purchasing an additional 629 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Zimmer Biomet by 26.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,511 shares of the medical equipment provider’s stock valued at $1,895,000 after purchasing an additional 3,633 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.3 %

NYSE:ZBH opened at $104.32 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a market cap of $20.77 billion, a PE ratio of 23.44, a PEG ratio of 1.95 and a beta of 1.02. Zimmer Biomet has a 52-week low of $97.69 and a 52-week high of $133.90. The stock has a 50-day simple moving average of $105.72 and a 200 day simple moving average of $107.38.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm earned $2.20 earnings per share. On average, sell-side analysts expect that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.